Clinical trial
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of…
NCT00401375 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00401375 |
|---|---|
| Title | Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI) |
| Official title | A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI) |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Post-Operative Ileus (POI) |
| Intervention type | Drug |
| Interventions | Methylnaltrexone, Placebo |
| Enrollment | 524 |
| Start date | Oct 31, 2006 |
| Primary completion | Feb 29, 2008 |
| Completion | Feb 29, 2008 |
| First posted | Nov 20, 2006 |
| Last update posted | Sep 4, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: